Stempeutics and MEDINET Partner for Innovative Stem Cell Therapy in Japan
Stempeutics India and MEDINET Japan have announced an option license agreement for Stempeucel, a cell therapy product for treating CLTI in Japan. This deal could lead to an exclusive license, allowing MEDINET to develop and commercialize Stempeucel in Japan. Financials include milestones and royalty payments.
- Country:
- India
MEDINET Japan and Stempeutics India, affiliates of the Manipal Education & Medical Group, have entered into an option license agreement for Stempeucel therapy aimed at chronic limb-threatening ischemia (CLTI) treatment in Japan. This strategic move could pave the way for an exclusive licensing agreement, enabling MEDINET to commercialize Stempeucel in the Japanese market.
The agreement positions Stempeutics for significant financial gains, with the upfront payment already received, alongside potential milestone and royalty revenues pending the exercise of the licensing option. While financial specifics remain undisclosed, this development marks a pivotal step in the international expansion of Stempeutics' regenerative treatments.
Currently approved in India and patented in Japan, Stempeucel has demonstrated efficacy in treating over 600 patients with CLTI. Manufactured in Bengaluru, the product will undergo further trials in Japan, bolstered by successful Indian clinical trial data. This collaboration is expected to bring advanced, life-changing treatment to Japanese patients suffering from severe CLTI.
Google News